Pseudomonas Aeruginosa Infection Treatment Market Synopsis

Pseudomonas Aeruginosa Infection Treatment Market Size Was Valued at USD 1.39 Billion in 2023 and is Projected to Reach USD 2.37 Billion by 2032, Growing at a CAGR of 6.11% From 2024-2032.

Pseudomonas is a type of bacteria found commonly in the environment in soil and water. There are many types of Pseudomonas but the one that most often causes infections in human beings is Pseudomonas aeruginosa, Pseudomonas aeruginosa can cause infections in the blood, lungs (pneumonia), or even in the other parts of the body after surgery. It is a serious health issue worldwide with a mortality rate ranging from 18% to 61%, Pseudomonas Aeruginosa Infection is treated by a combination of medicines and antibiotics.

• Pseudomonas aeruginosa is commonly found in the environment and can spread to people in healthcare settings when they are exposed to water or soil that is contaminated with these bacteria. Resistant strains of the germ are also very likely to spread from one person to another through contaminated hands, equipment, or surfaces.
• Pseudomonas aeruginosa has a prevalence of 7.1%–7.3% among all healthcare-associated infections. The most common site of this infection is pneumonia, and it is the most common Gram-negative organism identified in nosocomial pneumonia. The prevalence of P. aeruginosa is been increasing at a very fast rate.
• Moreover, if seen in intensive care unit (ICU) patients, these bacteria are responsible for an even higher percentage of healthcare-associated infections. A large international observational point-prevalence study of infections in ICU patients found that Pseudomonas aeruginosa represented around 16.2% of patient infections and was the cause of 23% of all ICU-acquired infections, with a respiratory source being the most common site of this infection.
• Pseudomonas aeruginosa infection cases are been largely increasing over the past decade. The treatment of Pseudomonas aeruginosa infections is generally done with antibiotics, antibiotic therapy with several other medicines is an important treatment. The medication for these types of infections includes aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin), carbapenems, cephalosporins, fluoroquinolones, penicillin with β-lactamase inhibitors (BLI), monobactams (aztreonam), fosfomycin and polymyxins.

Pseudomonas Aeruginosa Infection Treatment Market Trend Analysis

Increasing Prevalence of Serious Infections Caused by Pseudomonas Aeruginosa and Most of Them Being Nosocomial Infections

• The rising number of P. aeruginosa cases across the world is the primary factor that is boosting the demand for P. aeruginosa infection treatment. Today, Pseudomonas aeruginosa is one of the most common pathogens that may prove fatal, these bacteria cause severe nosocomial infections and also it is well-known for their multidrug resistance and hypervirulence. Infections caused by P. aeruginosa are critical to curate routinely.
• According to the Global Burden of Diseases, Injuries, and Risk Factors Study, a study on 33 bacterial genera or species across 11 infectious syndromes conducted in 2019, from 13·7 million infection-related deaths in 2019, there were 7·7 million deaths associated with the 33 bacterial pathogens and 5 leading pathogens—Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa were responsible for 54·9% of deaths. The number shows how the bacteria has proved to be fatal. Such severity of infections is the main reason behind the greater demand for effective treatments for the same.
• Moreover, despite the decline in the mortality rate of P. aeruginosa infected from approximately 90% when it was first discovered in 1882 up to now which is around 54%-56%, complete control over the infections is still not possible. For instance, the Centers for Disease Control and Prevention (CDC), estimated 51,000 healthcare-associated P aeruginosa infections in US hospitals occurring each year. Hence due to emerging infections, the need for treatments is also growing.

Rapidly Developing Multi-Drug Resistance (Antibiotic Resistance) In the Bacteria Along with Continued Development of Advanced Therapeutic Strategies

• Among all the nosocomial pathogens, Pseudomonas aeruginosa is recognized to be the major cause of morbidity and mortality. Pseudomonas aeruginosa infections are rising rapidly and these infections have no effective treatment. In addition to this, drug resistance (the nature of bacteria to develop resistance) is also growing rapidly across the world which has made the treatment even more complicated.
• Pseudomonas aeruginosa infections can generally be treated with antibiotics. But, now the multi-drug resistance in Pseudomonas aeruginosa and the increase in the number of these bacteria in healthcare settings like hospitals or nursing homes are making the treatment more difficult. For example, In year 2017, multidrug-resistant P. aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States alone further it is found that P. aeruginosa infected about 51,000 patients in the US each year, with about 6700 being multidrug-resistant
• With this, the bacteria are constantly finding new ways to resist the effects of the antibiotics used to treat the infections they cause and such a multi-drug resistant nature of Pseudomonas aeruginosa has resulted in an urgent need for new research and innovation in the antibacterial field to develop the most effective treatment for such infections, and ultimately serving as an opportunity for the market of pseudomonas aeruginosa infection treatment.

Pseudomonas Aeruginosa Infection Treatment Market Segment Analysis:

Pseudomonas Aeruginosa Infection Treatment market segments cover the Treatment Type, Drug Type, Route of Administration, and Distribution Channel.

By Treatment Type, Combination Treatment segment is expected to dominate the market during the forecast period

• Combination antibiotic therapy holds the largest share in the P. aeruginosa Infection Treatment Market. The reason behind the success of the segment is the extensive use of combination antibiotic therapy for severe pseudomonal infections.  Combination treatment is standard practice across many hospitals and healthcare centers when it comes to the treatment of P. aeruginosa.
• Combination therapy proves to be very effective on multi-drug resistant bacteria, some of the benefits include in vitro antibiotic synergy, prevention of the emergence of bacterial resistance while receiving therapy, and improved adequacy of empiric therapy.
• Combination therapy also helps in increasing compliance and efficacy, faster onset of action and it also reduces side effects and overall cost. These factors are leading to a rise in demand for combination therapy for the treatment of Pseudomonas aeruginosa infection which is ultimately fuelling the growth of the Pseudomonas Aeruginosa Infection Treatment Market.

By Distribution Channel, the Hospital Pharmacy segment held the largest share of 45.8% in 2022

• Hospital pharmacies play a pivotal role as the largest distribution channel segment for the Pseudomonas Aeruginosa Infection Treatment Market. These pharmacies serve as crucial hubs within healthcare ecosystems, acting as a bridge between healthcare providers and patients.
• The prevalence of Pseudomonas Aeruginosa infections, known for their resistance to many antibiotics, necessitates specialized medications and treatments that are often available exclusively through hospital pharmacies. These establishments are equipped to handle the complexities of infectious disease management, ensuring timely access to advanced pharmaceutical interventions.
• In hospital pharmacies, healthcare professionals collaborate closely to tailor treatment plans based on the specific needs of patients battling Pseudomonas Aeruginosa infections. The dynamic nature of these settings enables rapid response to emerging challenges, allowing for the efficient distribution of cutting-edge medications and therapeutic solutions.
• Additionally, hospital pharmacies serve as educational hubs, providing crucial information to both healthcare practitioners and patients about the latest advancements in Pseudomonas Aeruginosa infection treatment. As central pillars of the healthcare infrastructure, hospital pharmacies contribute significantly to the accessibility, efficacy, and safety of treatments for this challenging infection, fostering a comprehensive and patient-centered approach to care.

Pseudomonas Aeruginosa Infection Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• Increasing healthcare-associated infections (HAI) and rising technological innovations in the medical field in North American countries are mainly expected to drive the growth of the market in the region. According to the Statistics, more than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Also, according to a multistate point prevalence survey conducted by the CDC in 2014 shows that about 4% of hospitalized patients suffered from at least one of the HAI in the United States. 
• Further speaking about Canada, according to a report published in January 2022, each year, many Canadians acquire an infection during their hospital stay that increases mortality and costs heavily to the healthcare system. It is estimated that around 220,000 Canadian patients develop healthcare-associated infections (HAIs). Hence, such rising infection across developed countries like the US and Canada is expected to propel the market growth over the forecast period.
• In addition to this, government initiatives and funding for combatting antimicrobial resistance are continued in these countries and such implementation of national initiatives aimed at financially incentivizing the research and development (R&D) of antibiotics is boosting the market growth in the region.

Pseudomonas Aeruginosa Infection Treatment Market Top Key Players:

• Pfizer Inc. (USA)
• Merck & Co., Inc. (USA)
• Johnson & Johnson (USA)
• Cubist Pharmaceuticals (USA)
• Melinta Therapeutics (USA)
• Mylan N.V.  (USA)
• GlaxoSmithKline plc (UK)
• AstraZeneca plc (UK)
• Novartis AG (Switzerland)
• Roche Holding AG (Switzerland)
• Basilea Pharmaceutica (Switzerland)
• Sandoz International GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• BioMérieux SA (France)
• Sanofi (France)
• Cipla Ltd. (India)
• Lupin Limited (India)
• Dr. Reddy's Laboratories (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Biocon Ltd. (India)
• Shionogi & Co., Ltd. (Japan)
• Meiji Seika Pharma Co., Ltd. (Japan) and Other Major Players

Key Industry Developments in the Pseudomonas Aeruginosa Infection Treatment Market:

• In October 2023, BiomX Inc. successfully concluded patient dosing in Phase 1b/2a Part 2 trial of BX004, a pioneering phage cocktail designed for treating chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa., BX004 addresses a critical unmet need for effective treatments against persistent lung infections. Jonathan Solomon, CEO of BiomX, expresses optimism following the positive reception of Part 1 results at esteemed conferences, emphasizing growing interest in the BX004 program within the cystic fibrosis community. The company's commitment to advancing phage therapies positions BX004 as a promising solution.
• In December 2022, Clarametyx Biosciences began a Phase I clinical trial of CMTX-101, an immune-enabling antibody therapy, to treat community-acquired bacterial pneumonia.
• In March 2022, The National Institute of Allergy and Infectious Diseases (NIAID) awarded a roughly USD 2.5 million grant to two University of Maryland School of Pharmacy (UMSOP) staff members to examine how infections caused by the bacteria Pseudomonas aeruginosa develop multidrug resistance.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY TREATMENT TYPE (2017-2032)
   1. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. MONOTHERAPY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. COMBINATION THERAPY
7. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DRUG TYPE (2017-2032)
   1. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. CEPHALOSPORIN
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. AMINOGLYCOSIDE
   5. CARBAPENEM
   6. MONOBACTAM
   7. OTHERS
8. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY ROUTE OF ADMINISTRATION (2017-2032)
   1. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. NASAL
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. ORAL
   5. INTRAVENOUS
9. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DISTRIBUTION CHANNEL (2017-2032)
   1. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITAL PHARMACY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. RETAIL PHARMACY
   5. ONLINE PHARMACY
10. COMPANY PROFILES AND COMPETITIVE ANALYSIS
    1. COMPETITIVE LANDSCAPE
       1. Competitive Positioning
       2. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT Market Share By Manufacturer (2022)
       3. Industry BCG Matrix
       4. Heat Map Analysis
       5. Mergers & Acquisitions
    2. PFIZER INC. (USA)
       1. Company Overview
       2. Key Executives
       3. Company Snapshot
       4. Role of the Company in the Market
       5. Sustainability and Social Responsibility
       6. Operating Business Segments
       7. Product Portfolio
       8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
       9. Key Strategic Moves And Recent Developments
       10. SWOT Analysis
    3. PFIZER INC. (USA)
    4. MERCK & CO., INC. (USA)
    5. JOHNSON & JOHNSON (USA)
    6. CUBIST PHARMACEUTICALS (USA)
    7. MELINTA THERAPEUTICS (USA)
    8. MYLAN N.V.(USA)
    9. GLAXOSMITHKLINE PLC (UK)
    10. ASTRAZENECA PLC (UK)
    11. NOVARTIS AG (SWITZERLAND)
    12. ROCHE HOLDING AG (SWITZERLAND)
    13. BASILEA PHARMACEUTICA (SWITZERLAND)
    14. SANDOZ INTERNATIONAL GMBH (GERMANY)
    15. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
    16. BIOMÉRIEUX SA (FRANCE)
    17. SANOFI (FRANCE)
    18. CIPLA LTD. (INDIA)
    19. LUPIN LIMITED (INDIA)
    20. DR. REDDY'S LABORATORIES (INDIA)
    21. SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
    22. BIOCON LTD. (INDIA)
    23. SHIONOGI & CO., LTD. (JAPAN)
    24. MEIJI SEIKA PHARMA CO., LTD. (JAPAN)
11. GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segment1
       4. Historic And Forecasted Market Size By Segment2
       5. Historic And Forecasted Market Size By Segment3
       6. Historic And Forecasted Market Size By Segment4
       7. Historic And Forecasted Market Size By Segment5
       8. Historic And Forecasted Market Size By Segment6
       9. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
12. INVESTMENT ANALYSIS
13. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY TREATMENT TYPE
TABLE 008. MONOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 009. COMBINATION THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DRUG TYPE
TABLE 011. CEPHALOSPORIN MARKET OVERVIEW (2016-2028)
TABLE 012. AMINOGLYCOSIDE MARKET OVERVIEW (2016-2028)
TABLE 013. CARBAPENEM MARKET OVERVIEW (2016-2028)
TABLE 014. MONOBACTAM MARKET OVERVIEW (2016-2028)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 016. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY ROUTE OF ADMINISTRATION
TABLE 017. NASAL MARKET OVERVIEW (2016-2028)
TABLE 018. ORAL MARKET OVERVIEW (2016-2028)
TABLE 019. INTRAVENOUS MARKET OVERVIEW (2016-2028)
TABLE 020. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DISTRIBUTION CHANNEL
TABLE 021. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 022. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 023. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 025. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 026. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 027. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 028. N PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 029. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 030. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 031. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 032. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 033. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 034. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 035. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 036. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 037. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 038. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 039. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 043. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 044. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 045. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 046. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 047. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 048. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 049. ALLERGAN (US): SNAPSHOT
TABLE 050. ALLERGAN (US): BUSINESS PERFORMANCE
TABLE 051. ALLERGAN (US): PRODUCT PORTFOLIO
TABLE 052. ALLERGAN (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. PFIZER INC. (US): SNAPSHOT
TABLE 053. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 054. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 055. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. MERCK & CO. INC. (US): SNAPSHOT
TABLE 056. MERCK & CO. INC. (US): BUSINESS PERFORMANCE
TABLE 057. MERCK & CO. INC. (US): PRODUCT PORTFOLIO
TABLE 058. MERCK & CO. INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. ASTRAZENECA PLC (UK): SNAPSHOT
TABLE 059. ASTRAZENECA PLC (UK): BUSINESS PERFORMANCE
TABLE 060. ASTRAZENECA PLC (UK): PRODUCT PORTFOLIO
TABLE 061. ASTRAZENECA PLC (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 062. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 063. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 064. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. LUPIN PHARMACEUTICALS INC. (INDIA): SNAPSHOT
TABLE 065. LUPIN PHARMACEUTICALS INC. (INDIA): BUSINESS PERFORMANCE
TABLE 066. LUPIN PHARMACEUTICALS INC. (INDIA): PRODUCT PORTFOLIO
TABLE 067. LUPIN PHARMACEUTICALS INC. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. GILEAD SCIENCES INC. (US): SNAPSHOT
TABLE 068. GILEAD SCIENCES INC. (US): BUSINESS PERFORMANCE
TABLE 069. GILEAD SCIENCES INC. (US): PRODUCT PORTFOLIO
TABLE 070. GILEAD SCIENCES INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): SNAPSHOT
TABLE 071. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): BUSINESS PERFORMANCE
TABLE 072. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): PRODUCT PORTFOLIO
TABLE 073. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. BRISTOL-MYERS SQUIBB CO. (US): SNAPSHOT
TABLE 074. BRISTOL-MYERS SQUIBB CO. (US): BUSINESS PERFORMANCE
TABLE 075. BRISTOL-MYERS SQUIBB CO. (US): PRODUCT PORTFOLIO
TABLE 076. BRISTOL-MYERS SQUIBB CO. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. PARI MEDICAL HOLDING GMBH (GERMANY): SNAPSHOT
TABLE 077. PARI MEDICAL HOLDING GMBH (GERMANY): BUSINESS PERFORMANCE
TABLE 078. PARI MEDICAL HOLDING GMBH (GERMANY): PRODUCT PORTFOLIO
TABLE 079. PARI MEDICAL HOLDING GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. JANSSEN PHARMACEUTICALS INC. (BELGIUM): SNAPSHOT
TABLE 080. JANSSEN PHARMACEUTICALS INC. (BELGIUM): BUSINESS PERFORMANCE
TABLE 081. JANSSEN PHARMACEUTICALS INC. (BELGIUM): PRODUCT PORTFOLIO
TABLE 082. JANSSEN PHARMACEUTICALS INC. (BELGIUM): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. AMPLIPHI BIOSCIENCES CORP (US): SNAPSHOT
TABLE 083. AMPLIPHI BIOSCIENCES CORP (US): BUSINESS PERFORMANCE
TABLE 084. AMPLIPHI BIOSCIENCES CORP (US): PRODUCT PORTFOLIO
TABLE 085. AMPLIPHI BIOSCIENCES CORP (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. HUMANIGEN INC (US): SNAPSHOT
TABLE 086. HUMANIGEN INC (US): BUSINESS PERFORMANCE
TABLE 087. HUMANIGEN INC (US): PRODUCT PORTFOLIO
TABLE 088. HUMANIGEN INC (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 089. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 090. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 091. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY TREATMENT TYPE
FIGURE 012. MONOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 013. COMBINATION THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY DRUG TYPE
FIGURE 015. CEPHALOSPORIN MARKET OVERVIEW (2016-2028)
FIGURE 016. AMINOGLYCOSIDE MARKET OVERVIEW (2016-2028)
FIGURE 017. CARBAPENEM MARKET OVERVIEW (2016-2028)
FIGURE 018. MONOBACTAM MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 020. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 021. NASAL MARKET OVERVIEW (2016-2028)
FIGURE 022. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 023. INTRAVENOUS MARKET OVERVIEW (2016-2028)
FIGURE 024. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 025. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 026. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 027. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)